These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

499 related items for PubMed ID: 17420609

  • 1. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [Abstract] [Full Text] [Related]

  • 2. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
    Gatto F, Barbieri F, Castelletti L, Arvigo M, Pattarozzi A, Annunziata F, Saveanu A, Minuto F, Castellan L, Zona G, Florio T, Ferone D.
    Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
    [Abstract] [Full Text] [Related]

  • 3. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
    Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, Kawamata T, Kubo O, Hori T, Takano K.
    Endocr J; 2007 Feb; 54(1):133-8. PubMed ID: 17159301
    [Abstract] [Full Text] [Related]

  • 4. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K.
    Endokrynol Pol; 2010 Feb; 61(2):178-81. PubMed ID: 20464704
    [Abstract] [Full Text] [Related]

  • 5. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A.
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [Abstract] [Full Text] [Related]

  • 6. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [Abstract] [Full Text] [Related]

  • 7. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
    Murabe H, Shimatsu A, Ihara C, Mizuta H, Nakamura Y, Nagata I, Kikuchi H, Nakao K.
    J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
    [Abstract] [Full Text] [Related]

  • 8. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
    Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR.
    Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
    [Abstract] [Full Text] [Related]

  • 9. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR.
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [Abstract] [Full Text] [Related]

  • 10. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage.
    Greenman Y, Melmed S.
    J Clin Endocrinol Metab; 1994 Sep; 79(3):724-9. PubMed ID: 7521350
    [Abstract] [Full Text] [Related]

  • 11. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
    Yu B, Zhang Z, Song H, Chi Y, Shi C, Xu M.
    Med Sci Monit; 2017 Apr 23; 23():1947-1955. PubMed ID: 28434012
    [Abstract] [Full Text] [Related]

  • 12. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
    Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, Quintella LP, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR.
    J Clin Endocrinol Metab; 2009 Jun 23; 94(6):1931-7. PubMed ID: 19293270
    [Abstract] [Full Text] [Related]

  • 13. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
    Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.
    J Endocrinol; 2016 Nov 23; 231(2):135-145. PubMed ID: 27587848
    [Abstract] [Full Text] [Related]

  • 14. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S.
    Endocr J; 2004 Apr 23; 51(2):227-36. PubMed ID: 15118275
    [Abstract] [Full Text] [Related]

  • 15. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression.
    Corbetta S, Ballaré E, Mantovani G, Lania A, Losa M, Di Blasio AM, Spada A.
    Eur J Clin Invest; 2001 Mar 23; 31(3):208-14. PubMed ID: 11264647
    [Abstract] [Full Text] [Related]

  • 16. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
    Vieria Neto L, Wildemberg LE, Colli LM, Kasuki L, Marques NV, Moraes AB, Gasparetto EL, Takiya CM, Castro M, Gadelha MR.
    PLoS One; 2013 Mar 23; 8(10):e77406. PubMed ID: 24098585
    [Abstract] [Full Text] [Related]

  • 17. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.
    Clin Endocrinol (Oxf); 2012 Mar 23; 76(3):407-14. PubMed ID: 21848909
    [Abstract] [Full Text] [Related]

  • 18. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec 23; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 19. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
    Panetta R, Patel YC.
    Life Sci; 1995 Dec 23; 56(5):333-42. PubMed ID: 7530798
    [Abstract] [Full Text] [Related]

  • 20. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
    Shimatsu A, Murabe H, Kamoi K, Suzuki Y, Nakao K.
    Endocr J; 1999 Feb 23; 46(1):113-23. PubMed ID: 10426575
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.